EcoDrugPlus

Smoothened Homolog

Ensembl ID : ENSSTUG00000048764
Gene Symbol: LOC115180083
3 Cross references
202 Possible Orthologues:

Sodium Channel Protein Type 2 Subunit Alpha-Like

Ensembl ID : ENSSTUG00000025875
Gene Symbol: LOC115195557
3 Cross references
258 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha B-Like

Ensembl ID : ENSSTUG00000023534
Gene Symbol: LOC115150314
3 Cross references
259 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha-Like

Ensembl ID : ENSSTUG00000023343
Gene Symbol: LOC115157561
3 Cross references
248 Possible Orthologues:

Sodium Channel Protein Type 8 Subunit Alpha-Like

Ensembl ID : ENSSTUG00000008454
Gene Symbol: LOC115150512
2 Cross references
210 Possible Orthologues:

Sodium Channel Protein Type 8 Subunit Alpha-Like

Ensembl ID : ENSSTUG00000039904
Gene Symbol: LOC115207906
2 Cross references
210 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSSTUG00000038914
Gene Symbol: SCN4A
3 Cross references
192 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSSTUG00000009501
Gene Symbol: SCN4A
3 Cross references
191 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSSTUG00000013452
Gene Symbol: SCN8A
3 Cross references
209 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSSTUG00000033206
Gene Symbol: SCN8A
3 Cross references
209 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSSTUG00000023232
Gene Symbol: LOC115166145
3 Cross references
199 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSSTUG00000003932
Gene Symbol: LOC115168392
3 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).